Pharmaceuticals, Biotechnology and Life Sciences
Republic of Ireland’s Health Service Executive (HSE) and Sobi have signed a supply deal to offer people with with haemophilia haemophilia…
Roche has reported interim results from the phase III HAVEN 2 study evaluating emicizumab prophylaxis in children less than 12 years of age with haemophilia A and inhibitors to factor VIII.
Shire will now be able to use its Adynovate for treating heamophilia A in children younger than 12 years of age, as the the U.S. Food and Drug Administration (FDA) has approved it for that age group. The FDA has also…
Roche’s phase III study of haemophilia drug emicizumab prophylacis for 12 yearolds and older has met its primary endpoint, as…
Eurostars grant awarded to international consortium including Abzena company, Antitope, for development of novel treatment for clotting disorders